This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
PCN pharmacy lead Gareth Malson offers his top ten tips for supporting people with diabetes to improve control of their condition at regular review The prevalence of diabetes is continuing to rise at an alarming rate. In 2023-24, the national diabetes register increased by around 21 people every hour, with 4.6m
Voices Q&A Profiles Biotech Spotlight First 90 Days Opinions Topics Biotech Commercialization Leadership Manufacturing Patient Pharma Policy & Regulation Research & Development Library Events Press Releases PharmaVoice 100 Nominate 2024 PV100 2023 PV100 Sign up Search Sign up Search An article from Megablockbusters are the holy grail.
A recent study published in Springer Medizin has identified insulinoma-associated protein 2 autoantibody (IA-2A) positivity as a significant biomarker for disease progression in individuals at risk of type 1 diabetes (T1D). billion in 2023 to $9.9 billion in 2023 to $9.9 per cent, increasing from $2.2
Last Words Substance use disorders (SUD) are similar to other chronic relapsing medical conditions such as diabetes mellitus, congestive heart failure/cardiomyopathy, chronic obstructive pulmonary disorder, and cancer. 2023 Jan 1;53(1):140-2. 2022; 06/26/2023. 2023 Jun 1;36:89-91. 2023 Aug 1;89(2):231. 2023 [book].
According to the Derwent World Patents Index from Clarivate, the number of pharma patents filed and granted by Indian companies has risen from 1,590 in 2013 to 8,793 in 2023, representing an increase from 0.5 per cent of global patents to almost 2 per cent.
The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 Due to their ability to effectively treat metabolic-related disorders, such as obesity and type 2 diabetes, the 11 approved GLP-1Rs generated sales of $37.2 billion in 2030. billion in 2030.
This brings the pass rates back down almost to November 2022 levels of 56%, following a 10% rise to 66% in November 2023. Just 58% of trainee pharmacists passed the General Pharmaceutical Council (GPhC)'s national registration assessment this November, the regulator has announced.
Products in this category are often prescribed by practitioners, such as nephrologists for renal care or diabetologists for managing diabetes. billion in 2023 and is expected to grow at a CAGR of 8.4 per cent from 2023 to 2030. per cent from 2024 to 2030. Whereas the global vitamin supplements market size was estimated at $48.51
Early 2025: Medicare penalties take effect for providers who failed to meet 2023 quality metrics. Chronic Condition Management: By providing targeted interventions for conditions like diabetes and hypertension, PCMs improve outcomes and reduce costs. This underscores the urgency of compliance in subsequent years.
In order to cover a large category of medicines, 29 Major therapeutic groups like antibiotics and anti-infectives, anti-cancer, anti-diabetics, cardiovascular drugs, analgesics and antipyretic, anti-allergic, gastro-intestinal agents, vitamins and minerals, food supplements/nutraceuticals, topical medicines etc have been covered in PMBJP basket.
Health tech investments are showing signs of resilience following the perilous lows of 2022 and 2023: Just this past month, two startups that analysts believe might be getting ready for IPOs raised more than $100 million in late-stage funding rounds.
Beyond these official sources, various healthcare societies and associations also contribute by publishing practical guides relevant to their specific disciplines.
The goal, first announced in November 2023, is to improve longevity and reduce disparities caused by heart- and diabetes-related diseases by 5% by 2030 and deaths due to screenable cancers by 20% by 2030. Read the rest…
The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 billion in 2023 to $9.9 The type 1 diabetes (T1D) market across the seven major markets (7MM*) is set to grow at a compound annual growth rate (CAGR) of 13.3 billion in 2023 to $9.9
1 The FDA provisions in the Consolidated Appropriations Act of 2023 allow IND applicants to use other methods besides animal testing to establish a drug’s safety and efficacy. link] Consolidated Appropriations Act of 2023, HR 2617, 117th Cong (2023). 3,6 REFERENCES FDA drug approval process infographic (horizontal).
Furthermore, delays in medication access can exacerbate chronic conditions, such as diabetes, hypertension, and asthma, leading to increased hospitalization rates. Patients may be unable to obtain critical medications, resulting in poor adherence and negative outcomes.
Related Videos Related Content Advertisement June 27th 2025 Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP Luke Halpern, Assistant Editor June 3rd 2025 S2.
Estimates vary for how many patients with either obesity or diabetes stop using the drugs, but one 2024 study pegged the discontinuation between 50% and 75% within a year. Discontinuation rates soar The high rate of discontinuation among GLP-1 users remains a prime burden to keeping patients on the drugs.
6 The CDC reported 216 pediatric deaths from influenza during the 2024-2025 season—surpassing the previous nonpandemic season high of 207 deaths in 2023- 2024. Those 5 years and younger or with underlying health conditions are especially at risk for serious or even life-threatening complications.
The Zituvio range of products contains active ingredients sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
help teams generate draft copy, A/B test headlines, and adapt content across therapeutic areas—whether it’s for Dupixent in dermatology or Ozempic in diabetes care. Pharma companies using AI to streamline compliance workflows have reported up to 40% reduction in review timelines, according to a 2023 IQVIA study.
One of the most transformative areas they are leading is in the management of diabetes, particularly through continuous glucose monitors (CGMs) and wearable technologies. For individuals with diabetes, CGMs provide real-time data, allowing for earlier intervention and prevention of glycemic emergencies.
They are also more likely to have diabetes, pain, and disability than other groups. Improving cultural humility in pharmacy education: a focus on diabetes management during religious fasting. 11 STEPPING UP A LEVEL Pharmacy teams can also speak to and for their communities. Pharmacotherapy. 2007;27(7):1062-1079. doi:10.1592/phco.27.7.1062
Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.
Data collection spanned January 2020 to March 2023. This study examines herbal supplement prevalence, pharmacist interventions, and their impact on oncology treatment safety. Materials and Methods A survey-based observational study was conducted at the UC Davis Comprehensive Cancer Center.
This phase 1b clinical trial, conducted between September 2023 and November 2024, was designed to build on promising preclinical data that demonstrated improved efficacy and tolerability with continuous SC lenalidomide delivery in murine MM models.
The retrospective cohort study included all patients who met the criteria for the Medicare HRRP COPD model discharged between May 2021 and August 2023. The researchers included 187 patients and 92 patients in the pre- and postimplementation groups, respectively.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content